IngeCELL
VigiCell continually seeks to improve each component of its predictive toxicology platform via in-house development, co-development or acquisition.
VigiCell is a service provider: we never compete with our customers.
IngeCELL is a collaborative research project which was accredited in January 2006 by the world-class competitiveness cluster and is being funded by Paris-region local authorities and the French State. 
et financé par le comité de financeur : CG94, CG91, CG92, CG78, IdF, DGE
Background:
Human embryonic stem cells (hESCs) represent a promising field of investigation for the biomedicine of the future. The cells' almost unlimited ability to proliferate and give rise to all cell types in the human body has triggered great expectations and could revolutionize regenerative medicine. In the short term, the in vitro use of hESCs may result in better drug screening and predictive toxicology tests.
Objectives:
IngeCELL is a collaborative research project which pools private- and public-sector knowledge, skills and resources in the hESC sector :
- production of a range of organ-specific human cells (endothelial cells, hepatocytes, neurones, muscle cells, cardiomyocytes, haematopoietic cells, etc.) in order to build up an industrial offering which corresponds to both today's markets (e.g. drug screening and toxicological studies) and future opportunities (e.g. cell therapy).
- build and structure a globally competitive, visible and attractive cluster dedicated to fundamental hESC research and the development of applications.
Partners:
IngeCELL The IngeCELL project includes eleven academic research groups from the Paris region. All have acknowledged expertise in the field of stem cells and are starting to study hESCs in collaboration with the Généthon sequencing lab and six biotech SMEs focused on cell culture, cell differentiation and cell applications.
cellules ES (lignée H9) , photo : INSERM U602
